상세 보기
초록
This study was conducted to analyze cost-utility of bosentan versus iloprost indicated for pulmonary arterial hypertension (PAH) in a Korean healthcare setting from a payer’s perspective. We constructed a Markov model to estimate total costs and outcomes for 1-year time horizon in a hypothetical cohort of 50-year-old patients with PAH. Base analysis showed that bosentan resulted in KW 5.5 billions saving and 18 quality-adjusted life year (QALY) gains per 100 patients compared to iloprost. Bosentan as a dominant strategy was found to be robust through various sensitivity analyses.
키워드
cost-effectiveness; cost-utility; pulmonary arterial hypertension; bosentan; iloprost
- 제목
- 우리나라 폐동맥고혈압환자에 대한 Bosentan과 Iloprost의 비용-효용 분석
- 제목 (타언어)
- Cost-Utility Analysis of Bosentan Versus Iloprost in Korean Patients with Pulmonary Arterial Hypertension
- 저자
- 손현순; 이태진
- 발행일
- 2010-04
- 저널명
- 약 학 회 지
- 권
- 54
- 호
- 2
- 페이지
- 126 ~ 133